Dr. Salman Ahmed

Therapeutic potentials of crocin in medication of neurological disorders

• Authors Details :  
• Salman Ahmed,  
• Muhammad Mohtasheemul Hasan,  
• Mojtaba Heydari,  
• Abdur Rauf ,  
• Saud Bawazeer,  
• Tareq Abu-izneid,  
• Maksim Rebezov,  
• Mohammad Ali Shariati,  
• Maria Daglia,  
• Kannan Rr. Rengasamy

Journal title : Food and Chemical Toxicology

Publisher : Elsevier BV

Print ISSN : 0278-6915

Page Number : 111739

Journal volume : 145

45 Views Reviews Article

Neurological sicknesses are severe, multifactorial, debilitating disorders that may cause neurodegeneration. Neuroprotection protects the structure and capacity of neurons from affronts emerging from cell injuries instigated by an assortment of specialists or neurodegenerative diseases. Various neurodegenerative diseases, including Alzheimer's, Parkinson's, and epilepsy, afflict many people worldwide, with increasing age representing the leading risk factor. Crocin is a natural carotenoid compound with therapeutic potential in managing neurological disease. In this review, we focused on the therapeutic capabilities of Crocin as a neuroprotective agent. The general neuroprotective impact and the various conceivable essential components identified with Crocin have been examined. In light of the substantial proof indicating the neuro-pharmacological viability of Crocin to different exploratory standards, it is concluded that Crocin exerts direct antioxidant, antiapoptotic and anti-inflammatory activities by multiple signalling pathways. Besides, Crocin was found to elevate dopamine levels in the brain during the experimental model of Parkinson's disease. Thus, this compound has been demonstrated to be a promising option for treating neurodegenerative diseases with few adverse effects. It should be further considered as a potential contender for neuro-therapeutics, concentrating on the mechanistic and clinical evidence for its effects.

Article DOI & Crossmark Data

DOI : https://doi.org/10.1016/j.fct.2020.111739

Article Subject Details

• Medicine
• Neurourology
• Pharmacognosy
• Pharmacology
• Pharmacology and toxicology
• Pharmacy

Article Keywords Details

• Antiapoptotic
• Antioxidant
• Crocin
• Flavonoids
• Neurological disorders
• Therapeutic potential

Article File

Full Text PDF

---

---

Article References

• (1). 10.1002/(SICI)1099-1573(200005)14:3<149::AID-PTR665>3.0.CO;2-5
• (2). 10.1016/j.pbb.2005.06.007
• (3). 10.1016/j.fct.2019.110646
• (4). 10.1016/j.biopha.2018.01.113
• (5). 10.3390/ijms20092313
• (6). 10.3390/ijms20225570
• (7). 10.1016/j.pbb.2015.10.011
• (8). 10.1016/j.biochi.2019.02.011
• (9). 10.14581/jer.15009
• (10). 10.1021/acschemneuro.7b00101
• (11). 10.3109/10520295.2014.890741
• (12). 10.1016/j.fitote.2011.06.001
• (13). 10.1016/j.ynstr.2018.05.003
• (14). 10.1080/10408398.2013.879467
• (15). 10.3389/fnins.2019.00249
• (16). 10.1159/000439026
• (17). 10.1111/jphp.12456
• (18). 10.3389/fnins.2019.00560
• (19). 10.1155/2018/4067597
• (20). 10.4103/1673-5374.253509
• (21). 10.4236/jbbs.2013.33031
• (22). 10.2174/1570159X13666150716165726
• (23). 10.1021/acs.jafc.6b04398
• (24). 10.1016/S0306-4522(00)00041-5
• (25). 10.1007/s00213-013-3293-4
• (26). 10.1021/jf300589c
• (27). 10.1016/j.ejphar.2011.05.012
• (28). 10.2478/s11658-013-0092-1
• (29). 10.1016/j.seizure.2013.04.015
• (30). 10.1161/01.STR.0000126044.83777.f4
• (31). 10.1007/s12565-018-0457-7
• (32). 10.1002/ptr.3011
• (33). 10.1002/ptr.3566
• (34). 10.1007/s11418-017-1150-1
• (35). 10.3389/fphar.2018.01555
• (36). 10.1016/j.pneurobio.2018.05.001
• (37). 10.1016/j.apjtb.2015.07.015
• (38). 10.1016/j.ynstr.2018.04.002
• (39). 10.3109/03639040903140589
• (40). 10.1016/j.phymed.2013.07.013
• (41). 10.1016/S2221-1691(13)60060-X
• (42). 10.3109/03639045.2014.902466
• (43). 10.1093/advances/nmz047
• (44). 10.1007/s10570-013-9970-y
• (45). 10.1155/2019/9454913
• (46). 10.3389/fnins.2019.00043
• (47). 10.1007/s11064-016-1905-1
• (48). 10.1016/j.brainresbull.2019.01.004
• (49). 10.2174/1570159X12666140923205715
• (50). 10.3389/fphar.2014.00147
• (51). 10.1016/j.ejphar.2010.09.003
• (52). 10.1016/j.bbagen.2006.11.012
• (53). 10.1155/2013/239854
• (54). 10.1016/j.bbadis.2004.06.008
• (55). 10.1016/j.lfs.2016.04.028
• (56). 10.1016/j.bbr.2006.06.005
• (57). 10.1016/j.bbr.2007.06.001
• (58). 10.1055/a-0732-5757
• (59). 10.1016/j.exer.2012.11.011
• (60). 10.1016/j.ijbiomac.2017.02.095
• (61). 10.1590/0004-282X20160131
• (62). 10.1016/j.neuro.2015.12.010
• (63). 10.4103/2221-1691.239426
• (64). 10.1007/s10495-010-0463-2
• (65). 10.1007/s00580-019-02981-4
• (66). 10.1016/j.phrs.2020.104730
• (67). 10.1002/cbf.2858
• (68). 10.2174/1381612825666190425163424
• (69). 10.3389/fphar.2018.00715
• (70). 10.3390/molecules24081583
• (71). 10.1016/S0024-3205(01)01357-1
• (72). 10.1016/j.jad.2014.11.035
• (73). 10.1016/S1734-1140(12)70735-1
• (74). 10.2174/092986707780597961
• (75). 10.1046/j.1528-1157.2001.042suppl.3008.x
• (76). 10.1016/j.phymed.2010.10.019
• (77). 10.2174/157015909787602823
• (78). 10.1016/j.jstrokecerebrovasdis.2012.10.008
• (79). 10.1016/j.neulet.2015.02.016
• (80). 10.1016/j.jphs.2017.08.007
• (81). 10.1038/aps.2010.186
• (82). 10.1016/j.ejphar.2010.09.081
• (83). 10.1007/s11655-010-0145-5
• (84). 10.3164/jcbn.11-01
• (85). 10.5853/jos.2016.00206
• (86). 10.1016/j.neuint.2015.07.011
• (87). 10.1016/j.ejmech.2017.09.068
• (88). 10.1186/s12979-018-0132-9
• (89). 10.3389/fphar.2019.00440
• (90). 10.1016/j.brainres.2006.12.064

---

More Article by Dr. Salman Ahmed